Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.

Abstract

Mice bearing either of the two rapidly growing mouse leukemias, L1210 or P388, or the slow-growing B16 melanoma responded to i.p. injections of Macromomycin B (NSC 170105) with significant increases in life-span. The maximal increases in life-span obtained in these experiments were 37% for L1210, 68% for P388, and 120% for B16. In addition, there were 7 of 30 cures for varying doses of Macromomycin in the B16 melanoma. Activity of over 50% increase in life-span in B16 was obtained with a daily i.p. injection on Days 1 to 9 of 16 to 40 mg/kg. Animals that had received s.c. implanted Lewis lung tumors responded to either single or repeated injections (8 to 16 mg/kg) given at the site of tumor implant by a marked reduction in growth of the primary tumor, increased life-span, and some cures. The same doses were without effect when administered i.p. The reported activity of Macromomycin against L1210, P388 leukemias, B16 melanoma, and Lewis lung carcinoma make it a good candidate for development for clinical trial against human solid tumors. A new method of evaluating activity against solid tumors, "responder analysis," is also presented.

• Authors: M M Lippman, W R Laster, B J Abbott, J Venditti, M Baratta
• Journal: Cancer research (Cancer Res) Vol. 35 Issue 4 Pg. 939-45 (Apr 1975) ISSN: 0008-5472 [Print] United States
• PMID: 1116151 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• Bacterial Proteins

Topics

• Animals
• Antibiotics, Antineoplastic (administration & dosage, therapeutic use)
• Bacterial Proteins (therapeutic use)
• Evaluation Studies as Topic
• Leukemia L1210 (drug therapy)
• Leukemia, Experimental (drug therapy)
• Lung Neoplasms (drug therapy)
• Melanoma (drug therapy)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred C57BL
• Mice, Inbred DBA
• Neoplasm Transplantation
• Neoplasms, Experimental (drug therapy)